Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study

BMJ. 2013 Oct 1:347:f5577. doi: 10.1136/bmj.f5577.

Abstract

Objective: To determine the comparative effectiveness of exercise versus drug interventions on mortality outcomes.

Design: Metaepidemiological study.

Eligibility criteria: Meta-analyses of randomised controlled trials with mortality outcomes comparing the effectiveness of exercise and drug interventions with each other or with control (placebo or usual care).

Data sources: Medline and Cochrane Database of Systematic Reviews, May 2013.

Main outcome measure: Mortality.

Data synthesis: We combined study level death outcomes from exercise and drug trials using random effects network meta-analysis.

Results: We included 16 (four exercise and 12 drug) meta-analyses. Incorporating an additional three recent exercise trials, our review collectively included 305 randomised controlled trials with 339,274 participants. Across all four conditions with evidence on the effectiveness of exercise on mortality outcomes (secondary prevention of coronary heart disease, rehabilitation of stroke, treatment of heart failure, prevention of diabetes), 14,716 participants were randomised to physical activity interventions in 57 trials. No statistically detectable differences were evident between exercise and drug interventions in the secondary prevention of coronary heart disease and prediabetes. Physical activity interventions were more effective than drug treatment among patients with stroke (odds ratios, exercise v anticoagulants 0.09, 95% credible intervals 0.01 to 0.70 and exercise v antiplatelets 0.10, 0.01 to 0.62). Diuretics were more effective than exercise in heart failure (exercise v diuretics 4.11, 1.17 to 24.76). Inconsistency between direct and indirect comparisons was not significant.

Conclusions: Although limited in quantity, existing randomised trial evidence on exercise interventions suggests that exercise and many drug interventions are often potentially similar in terms of their mortality benefits in the secondary prevention of coronary heart disease, rehabilitation after stroke, treatment of heart failure, and prevention of diabetes.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Cardiovascular Agents / therapeutic use*
  • Comparative Effectiveness Research
  • Confounding Factors, Epidemiologic
  • Coronary Disease / drug therapy
  • Coronary Disease / mortality*
  • Coronary Disease / prevention & control
  • Coronary Disease / therapy*
  • Diuretics / therapeutic use
  • Exercise Therapy*
  • Female
  • Heart Failure / drug therapy
  • Heart Failure / mortality*
  • Heart Failure / prevention & control
  • Heart Failure / therapy*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Mortality / trends
  • Odds Ratio
  • Outcome Assessment, Health Care
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prediabetic State / drug therapy
  • Prediabetic State / mortality*
  • Prediabetic State / prevention & control
  • Prediabetic State / therapy*
  • Randomized Controlled Trials as Topic
  • Research Design
  • Stroke / drug therapy
  • Stroke / mortality*
  • Stroke / prevention & control
  • Stroke / therapy*

Substances

  • Anticoagulants
  • Cardiovascular Agents
  • Diuretics
  • Hypoglycemic Agents
  • Platelet Aggregation Inhibitors